Valuation : Immutep Limited

Market Cap 75.16M 53.72M 46.33M 43.6M 39.71M 74.64M 5.1B 516M 201M 2.59B 202M 197M 8.61B P/E 2027 *
-2.55x
P/E 2028 * -3.55x
Enterprise Value 41.16M 29.42M 25.37M 23.88M 21.75M 40.87M 2.79B 283M 110M 1.42B 110M 108M 4.71B EV / Sales 2027 *
20x
EV / Sales 2028 * 14.5x
Free-Float
96.98%
Yield 2027 *
-
Yield 2028 * -
1 day+6.25%
1 week-3.77%
Current month+6.25%
1 month+10.87%
3 months-3.77%
6 months-86.75%
Current year-87.71%
1 week 0.05
Extreme 0.047
0.05
1 month 0.05
Extreme 0.046
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 09/07/2014
Director of Finance/CFO - 01/03/2018
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 53 09/07/2014
Chairman 76 17/11/2017
Director/Board Member 57 12/02/2014
Date Insider Type Main position Quantity % Market Cap. Importance
18/3/26 Other

Chief Technology Officer

14,224,374 0.9652%
18/3/26 Other

Executive/Senior Manager

5,174,048 0.3511%
18/3/26 Other

Chief Executive Officer

18,477,395 1.2538%
Change 5-day change 1-year change 3-year change Capi.($)
+6.25%-3.77%-78.30%-82.11% 50.66M
+0.21%-1.70%+1.90%+18.18% 49.81B
+2.09%-0.81%+452.73%+517.81% 44.06B
-1.09%-0.73%+35.40%+16.04% 42.99B
-0.26%-3.58%+17.19%+72.80% 40.88B
-0.48%-3.09%+17.78%+49.80% 33.11B
-1.81%-5.94%+22.65%+115.79% 16.58B
-1.06%+3.29% - - 17.27B
-1.35%-2.32%+10.40%+25.90% 14.63B
-2.05%-5.44%+72.89%+36.51% 13.76B
Average -0.10%-2.42%+61.40%+85.64% 27.32B
Weighted average by Cap. -0.48%-1.79%+95.29%+124.41%

Financials

2027 *2028 *
Net sales 2.06M 1.47M 1.27M 1.19M 1.09M 2.04M 140M 14.13M 5.49M 70.98M 5.52M 5.4M 235M 1.56M 1.11M 959K 903K 823K 1.55M 106M 10.69M 4.16M 53.72M 4.18M 4.09M 178M
Net income -26.65M -19.04M -16.42M -15.46M -14.08M -26.46M -1.81B -183M -71.14M -920M -71.5M -69.94M -3.05B -32.59M -23.29M -20.09M -18.9M -17.22M -32.36M -2.21B -224M -87.01M -1.12B -87.44M -85.54M -3.73B
Net Debt -34M -24.3M -20.96M -19.72M -17.97M -33.76M -2.31B -234M -90.78M -1.17B -91.23M -89.25M -3.89B -52.6M -37.6M -32.42M -30.51M -27.8M -52.24M -3.57B -361M -140M -1.82B -141M -138M -6.02B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
01/09/26 $0.0510 +6.25% 4,914,512
31/08/26 $0.0480 -4.00% 4,218,452
28/08/26 $0.0500 0.00% 2,519,726
27/08/26 $0.0500 -3.85% 3,104,572
26/08/26 $0.0520 -3.70% 1,697,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0510AUD
Average target price
0.1033AUD
Spread / Average Target
+102.61%

Quarterly revenue - Rate of surprise